Gene therapy's future for treatment of myocardial infarction

Circulation: Cardiovascular Imaging

Volumn 6, Issue 3, 2013, Pages 360-362

  Kral, Brian G ^a   Kraitchman, Dara L ^b  

^a Division of Cardiology   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; CT and MRI; Editorials; Endothelium derived; Gene therapy; Nitric oxide

Indexed keywords

ANTIOXIDANT; CALCIUM; ENHANCED GREEN FLUORESCENT PROTEIN; EXTRACELLULAR SUPEROXIDE DISMUTASE; NITRIC OXIDE; OXIDIZING AGENT; PEROXYNITRATE; REACTIVE OXYGEN METABOLITE; SUPEROXIDE; SUPEROXIDE DISMUTASE; TROPONIN T; UNCLASSIFIED DRUG; SOD3 PROTEIN, MOUSE;

ADENO ASSOCIATED VIRUS; ADENO ASSOCIATED VIRUS SEROTYPE 9; BIOAVAILABILITY; BIOLUMINESCENCE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR MAGNETIC RESONANCE; ECHOCARDIOGRAPHY; EDITORIAL; ENHANCED GREEN FLUORESCENT GENE; EXTRACELLULAR SUPEROXIDE DISMUTASE GENE; GENE; GENE OVEREXPRESSION; GENE TARGETING; GENE THERAPY; GENE TRANSFER; GENETIC TRANSDUCTION; HEART FAILURE; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART MUSCLE CELL; HEART VENTRICLE REMODELING; INTRACELLULAR SIGNALING; NONHUMAN; OXIDATIVE STRESS; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROMOTER REGION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPERFUSION INJURY; UPREGULATION; ANGIOGENESIS; ANIMAL; BIOSYNTHESIS; CT AND MRI; EDITORIALS; ENZYMOLOGY; GENE VECTOR; HEART MUSCLE; METHODOLOGY; NITRIC OXIDE, ENDOTHELIUM-DERIVED; NOTE;

ANGIOGENESIS; CT AND MRI; EDITORIALS; GENE THERAPY; NITRIC OXIDE, ENDOTHELIUM-DERIVED;

ANIMALS; DEPENDOVIRUS; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; MYOCARDIAL INFARCTION; MYOCARDIUM; SUPEROXIDE DISMUTASE; VENTRICULAR REMODELING;

EID: 84880215076     PISSN: 19419651     EISSN: 19420080     Source Type: Journal    
DOI: 10.1161/CIRCIMAGING.113.000465     Document Type: Editorial

References (19)

1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Huffman MD, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Magid D, Marcus GM, Marelli A, Matchar DB, McGuire DK, Mohler ER, Moy CS, Mussolino ME, Nichol G, Paynter NP, Schreiner PJ, Sorlie PD, Stein J, Turan TN, Virani SS, Wong ND, Woo D, Turner MB; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation. 2013;127:e6-e245.
2. Heusch G. Cardioprotection: chances and challenges of its translation to the clinic. Lancet. 2013;381:166-175.
3. Gjesdal O, Bluemke DA, Lima JA. Cardiac remodeling at the population level-risk factors, screening, and outcomes. Nat Rev Cardiol. 2011;8:673-685.
4. Bolli R, Jeroudi MO, Patel BS, DuBose CM, Lai EK, Roberts R, McCay PB. Direct evidence that oxygen-derived free radicals contribute to post-ischemic myocardial dysfunction in the intact dog. Proc Natl Acad Sci U S A. 1989;86:4695-4699. (Pubitemid 19164616)
5. Werns SW, Lucchesi BR. Myocardial ischemia and reperfusion: the role of oxygen radicals in tissue injury. Cardiovasc Drugs Ther. 1989;2:761-769. (Pubitemid 19137903)
6. Obal D, Dai S, Keith R, Dimova N, Kingery J, Zheng YT, Zweier J, Velayutham M, Prabhu SD, Li Q, Conklin D, Yang D, Bhatnagar A, Bolli R, Rokosh G. Cardiomyocyte-restricted overexpression of extracellular superoxide dismutase increases nitric oxide bioavailability and reduces infarct size after ischemia/reperfusion. Basic Res Cardiol. 2012;107:305.
7. van Deel ED, Lu Z, Xu X, Zhu G, Hu X, Oury TD, Bache RJ, Duncker DJ, Chen Y. Extracellular superoxide dismutase protects the heart against oxidative stress and hypertrophy after myocardial infarction. Free Radic Biol Med. 2008;44:1305-1313.
8. Clarke R, Armitage J. Antioxidant vitamins and risk of cardiovascular disease. Review of large-scale randomised trials. Cardiovasc Drugs Ther. 2002;16:411-415. (Pubitemid 36255741)
9. Bolli R. Oxygen-derived free radicals and myocardial reperfusion injury: an overview. Cardiovasc Drugs Ther. 1991;5 suppl 2:249-268.
10. Konkalmatt PR, Beyers RJ, O'Connor DM, Xu Y, Seaman ME, French BA. Cardiac-selective expression of extracellular superoxide dismutase after systemic injection of adeno-associated virus 9 protects the heart against post-myocardial infarction left ventricular remodeling. Circ Cardiovasc Imaging. 2013;6:478-486.
11. Prasad KM, Smith RS, Xu Y, French BA. A single direct injection into the left ventricular wall of an adeno-associated virus 9 (AAV9) vector expressing extracellular superoxide dismutase from the cardiac troponin-T promoter protects mice against myocardial infarction. J Gene Med. 2011;13:333-341.
12. Konkalmatt PR, Wang F, Piras BA, Xu Y, O'Connor DM, Beyers RJ, Epstein FH, Annex BH, Hossack JA, French BA. Adeno-associated virus serotype 9 administered systemically after reperfusion preferentially targets cardiomyocytes in the infarct border zone with pharmacodynamics suitable for the attenuation of left ventricular remodeling. J Gene Med. 2012;14:609-620.
13. Fukai T, Folz RJ, Landmesser U, Harrison DG. Extracellular superoxide dismutase and cardiovascular disease. Cardiovasc Res. 2002;55:239-249. (Pubitemid 34775274)
14. Dulak J, Zagorska A, Wegiel B, Loboda A, Jozkowicz A. New strategies for cardiovascular gene therapy: regulatable pre-emptive expression of pro-angiogenic and antioxidant genes. Cell Biochem Biophys. 2006; 44:31-42. (Pubitemid 43099569)
15. Li Q, Bolli R, Qiu Y, Tang XL, Guo Y, French BA. Gene therapy with extracellular superoxide dismutase protects conscious rabbits against myocardial infarction. Circulation. 2001;103:1893-1898. (Pubitemid 32328404)
16. Seok J, Warren HS, Cuenca AG, Mindrinos MN, Baker HV, Xu W, Richards DR, McDonald-Smith GP, Gao H, Hennessy L, Finnerty CC, López CM, Honari S, Moore EE, Minei JP, Cuschieri J, Bankey PE, Johnson JL, Sperry J, Nathens AB, Billiar TR, West MA, Jeschke MG, Klein MB, Gamelli RL, Gibran NS, Brownstein BH, Miller-Graziano C, Calvano SE, Mason PH, Cobb JP, Rahme LG, Lowry SF, Maier RV, Moldawer LL, Herndon DN, Davis RW, Xiao W, Tompkins RG; Inflammation and Host Response to Injury, Large Scale Collaborative Research Program. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci U S A. 2013;110:3507-3512.
17. Gerber BL, Raman SV, Nayak K, Epstein FH, Ferreira P, Axel L, Kraitchman DL. Myocardial first-pass perfusion cardiovascular magnetic resonance: history, theory, and current state of the art. J Cardiovasc Magn Reson. 2008;10:18.
18. Hacein-Bey-Abina S, von Kalle C, Schmidt M, Le Deist F, Wulffraat N, McIntyre E, Radford I, Villeval JL, Fraser CC, Cavazzana-Calvo M, Fischer A. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med. 2003;348:255-256. (Pubitemid 36077924)
19. Jessup M, Greenberg B, Mancini D, Cappola T, Pauly DF, Jaski B, Yaroshinsky A, Zsebo KM, Dittrich H, Hajjar RJ; Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID) Investigators. Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure. Circulation. 2011;124:304-313.